Legal Issues Concerning the Primary Site Clause- Focusing on Supreme Court Decision 2023Da250746 Rendered on March 13, 2025 -
Korean Insurance Law Association · 30.10.2026 · 20 (3) · 93-126
DOI: 10.36248/kdps.2026.20.3.093 ↗Kurz gefasst
Fachartikel in der Zeitschrift Korean Insurance Law Association, online erschienen am 30.10.2026. Verfasst von Jun Yuop Kim.
Abstract (Originalsprache)
This article examines the legal nature and limitations of the so-called “primary site clause” in cancer insurance terms and conditions, and analyzes the significance of the Supreme Court Decision 2023Da250746 rendered on March 13, 2025, as well as the proper approach to future disputes of a similar nature. The primary site clause provides that, where a secondary or unspecified malignant neoplasm is diagnosed and the primary cancer is identified, the classification for the payment of insurance benefits shall be determined not by the metastatic site but by the primary site. In such cases, although the policyholder may reasonably expect to receive benefits for general cancer, the insurer pays only the benefits applicable to minor cancer on the ground that the primary site is a minor cancer. The Supreme Court held that the primary site clause is not merely a disease classification provision, but constitutes a material term of the insurance contract directly related to the existence of the insurer’s obligation to pay insurance benefits, the scope of coverage, and the amount payable. Accordingly, the Court ruled that where the insurer failed to specifically explain the clause, the insurer may not assert the clause as part of the contract. This decision is significant in that the Supreme Court clearly recognized that the primary site clause is subject to the insurer’s duty to explain, thereby confirming the application of incorporation control to such clauses. The Court also provided a practical standard by holding that, where benefits for minor cancer have already been paid, the insurer is not required to pay the full amount of general cancer benefits in addition, but only the difference between the two amounts. The Supreme Court did not decide whether the primary site clause itself constitutes an unfair term under the Act on the Regulation of Terms and Conditions. This article examines that separate question on the assumption that the clause has been incorporated into the contract. Since the clause serves the function of clarifying the classification of insurance benefits for secondary cancers, it cannot be categorically deemed invalid. Nevertheless, its application is not invariably favorable to policyholders even where the primary cancer is classified as general or high-cost cancer; the actual effect depends on the particular policy’s coverage structure. Where a minor cancer such as thyroid cancer metastasizes to distant organs, the severity and prognosis may differ substantially from those of localized disease. Such medical changes are relevant to substantive fairness, but do not by themselves establish an actuarial imbalance or determine the amount payable under a fixed-benefit policy.
Zitieren
APA
Kim, J. Y. (2026). Legal Issues Concerning the Primary Site Clause- Focusing on Supreme Court Decision 2023Da250746 Rendered on March 13, 2025 -. Korean Insurance Law Association, 20(3), 93-126. https://doi.org/10.36248/kdps.2026.20.3.093
Vancouver
Kim JY. Legal Issues Concerning the Primary Site Clause- Focusing on Supreme Court Decision 2023Da250746 Rendered on March 13, 2025 -. Korean Insurance Law Association. 2026;20(3):93-126. doi:10.36248/kdps.2026.20.3.093
BibTeX
@article{Kim2026,
author = {Kim, Jun Yuop},
title = {Legal Issues Concerning the Primary Site Clause- Focusing on Supreme Court Decision 2023Da250746 Rendered on March 13, 2025 -},
journal = {Korean Insurance Law Association},
year = {2026},
volume = {20},
number = {3},
pages = {93--126},
doi = {10.36248/kdps.2026.20.3.093}
}
EUVIMED